121 related articles for article (PubMed ID: 35370267)
1. Tetracyclines Enhance Anti-tumor T-Cell Responses Induced by a Bispecific T-Cell Engager.
Noguchi Y; Yamamoto Y; Iwahori K; Matsumoto M; Hirata M; Okuyama H; Shintani Y; Kumanogoh A; Wada H
Biol Pharm Bull; 2022; 45(4):429-437. PubMed ID: 35370267
[TBL] [Abstract][Full Text] [Related]
2. Tetracyclines enhance antitumor T-cell immunity via the Zap70 signaling pathway.
Tone M; Iwahori K; Hirata M; Ueyama A; Tani A; Haruta JI; Takeda Y; Shintani Y; Kumanogoh A; Wada H
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38621815
[TBL] [Abstract][Full Text] [Related]
3. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
[TBL] [Abstract][Full Text] [Related]
4. Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment.
Iwahori K; Shintani Y; Funaki S; Yamamoto Y; Matsumoto M; Yoshida T; Morimoto-Okazawa A; Kawashima A; Sato E; Gottschalk S; Okumura M; Kumanogoh A; Wada H
Sci Rep; 2019 Feb; 9(1):2636. PubMed ID: 30796310
[TBL] [Abstract][Full Text] [Related]
5. Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy.
Jang S; Song J; Kim N; Bak J; Jung K; Park YW; Park BC; Kim HM
Biomaterials; 2021 Apr; 271():120760. PubMed ID: 33774526
[TBL] [Abstract][Full Text] [Related]
6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
7. [Effect of interleukin-7 on the anti-tumor function of CD8(+) T cells in patients with non-small cell lung cancer].
Zhang XH; Wang HM; Jin L; Chang R; Zu FC; Li FZ; Ku CY
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(30):2429-2433. PubMed ID: 30138989
[No Abstract] [Full Text] [Related]
8. Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15.
Yao J; Ly D; Dervovic D; Fang L; Lee JB; Kang H; Wang YH; Pham NA; Pan H; Tsao MS; Zhang L
J Immunother Cancer; 2019 Jan; 7(1):17. PubMed ID: 30670085
[TBL] [Abstract][Full Text] [Related]
9. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
10. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
[TBL] [Abstract][Full Text] [Related]
11. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
12. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
[TBL] [Abstract][Full Text] [Related]
13. Tetracyclines Diminish
Florou DT; Mavropoulos A; Dardiotis E; Tsimourtou V; Siokas V; Aloizou AM; Liaskos C; Tsigalou C; Katsiari C; Sakkas LI; Hadjigeorgiou G; Bogdanos DP
Front Immunol; 2021; 12():739186. PubMed ID: 34899697
[TBL] [Abstract][Full Text] [Related]
14. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory Effect of Lentinan on Aberrant T Subsets and Cytokines Profile in Non-small Cell Lung Cancer Patients.
Wang XE; Wang YH; Zhou Q; Peng M; Zhang J; Chen M; Ma LJ; Xie GM
Pathol Oncol Res; 2020 Jan; 26(1):499-505. PubMed ID: 30460541
[TBL] [Abstract][Full Text] [Related]
16. CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer.
Bixby DL; Yannelli JR
Int J Cancer; 1998 Dec; 78(6):685-94. PubMed ID: 9833760
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of microRNA-10b expression in peripheral blood mononuclear cells in evaluating short- and long-term efficacy of chemotherapy for patients with advanced non-small-cell lung cancer.
Yang YL; Wang W; Xu LP
Neoplasma; 2018; 65(4):610-619. PubMed ID: 30064233
[TBL] [Abstract][Full Text] [Related]
19. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
20. Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
Yi JS; Ready N; Healy P; Dumbauld C; Osborne R; Berry M; Shoemaker D; Clarke J; Crawford J; Tong B; Harpole D; D'Amico TA; McSherry F; Dunphy F; McCall SJ; Christensen JD; Wang X; Weinhold KJ
Clin Cancer Res; 2017 Dec; 23(24):7474-7482. PubMed ID: 28951518
[No Abstract] [Full Text] [Related]
[Next] [New Search]
